🚴‍♀️ Biking and the Battle Against Itch! 🎙️

Live from the charming canals of Amsterdam at the EADV 2024 meeting, we sit down with the ever-energetic Dr. Perla Lansang from Toronto!

🍁 She's ditched cabs and metros to embrace the Dutch biking culture, even bringing her own bike across the pond! 🚲🌍 From navigating streets with more bikes than people 😲 to packing rain ponchos for unpredictable weather ☔, Dr. Lansang shares her love for the city.

🍽️ She's on a mission to find the best delectable mini Dutch pancakes topped with butter and powdered sugar 🥞✨. And while we couldn't coax the secret behind her infamous kale smoothie 🥬🥤, we dive into something even more exciting.

We explore late breaking fresh new data presented at EADV on nemolizumab, the new therapeutic targeting IL-31 that's set to revolutionize atopic dermatitis treatment! What does this new 56-week data from an interim analysis of the phase III ARCADIA long-term extension study mean for your patients?

🧪🔥 Discover how this game-changing drug offers rapid itch relief—some patients feel better in just days! 😮🧖‍♂️

We'll unpack nemolizumab’s long-term efficacy and safety in atopic dermatitis, discuss the stellar safety profile, and delve into how it is poised to transform patient care by improving sleep 😴 and overall quality of life 🌟.

This episode is packed with laughs 😂, insightful clinical pearls 🩺, and a sprinkle of Dutch delight! 🎧🌷

Learning Objectives:

1. Understand the pivotal role of IL-31 in atopic dermatitis and why nemolizumab's targeting of this cytokine is a breakthrough.
2. Review the design, key findings, and clinical significance of the Arcadia 1 and 2 long-term extension data up to 56 weeks.
3. Discuss the rapid efficacy and excellent safety profile of nemolizumab and its impact on itch relief, clearance and patient adherence.
4. Evaluate the clinical implications of integrating nemolizumab into practice and its potential to transform atopic dermatitis management.

ABOUT Dr. Perla Lansang, MD, FRCPC ( Dermatology)

Toronto, ON

Dr. Perla Lansang is a full-time staff dermatologist and associate professor in the Division of Dermatology, University of Toronto where she is the Division Head of Dermatology at Sunnybrook Health Sciences Centre. She is also cross appointed at the Section of Paediatric Dermatology at the Hospital for Sick Children, and the Division of Obstetric Medicine at Sunnybrook Health Sciences Centre.

She completed her medical school and dermatology residency at the University of the Philippines-Philippine General Hospital. Having done fellowships in paediatric dermatology at The Hospital for Sick Children and in advanced medical dermatology at Sunnybrook Health Sciences Centre, Dr. Lansang’s practice is a mixture of pediatric, adolescent, and adult dermatology, with a special focus on psoriasis, atopic dermatitis, cutaneous lymphoma, pregnancy dermatoses, and general medical dermatology. She has a special interest in immune-mediated skin diseases and has extensive clinical and research experience in many areas of immunodermatology.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

🎙 Amsterdam Stories, Delta Force & A Game-Changing Topical for Chronic Hand Eczema

🎉✨ Melinda Knows Best is BACK! 🚀💥

This time, Dr. Gooderham brings us a heavyweight showdown 🥊 between a new topical superhero 🦸‍♀️ and the reigning oral champ 💊 in the battle against Chronic Hand Eczema! reporting live from the European Academy of Dermatology and Venereology (EADV) Congress in the beautiful city of Amsterdam! 🇳🇱✨

In this special episode, we’re diving into the Delta Force Trial – a bold study comparing topical delgocitinib to oral alitretinoin for chronic hand eczema 💊🧴

👀 Dr. Gooderham spills the beans on impressive results, rapid relief, and how this new treatment is about to change the game for dermatologists and patients alike. 🎉

Oh, and don’t worry, we didn’t forget to ask about her Amsterdam adventures! 🌍 Did she run into some famous faces at dinner? 🍽️👀 Tune in for the scoop!

💡 Melinda Knows Best will keep you at the cutting edge of CHE breakthroughs. 👩‍⚕️✨

🎯 Learning Objectives:

1. Explore the Delta Force Trial Findings: Understand the significance of the Delta Force trial comparing topical delgocitinib to oral alitretinoin for chronic hand eczema. 🧴💊
2. Evaluate the Efficacy of Topicals vs Orals for chronic hand eczema: Learn about the early onset of symptom relief with delgocitinib, including i reductions in HEXI scores and patient quality of life improvements. ⏱️📉
3. Identify Key Real-World Implications: Discuss how this new topical treatment can shift the landscape for clinicians and patients, offering rapid, safe relief without the headaches (literally!) of oral therapies. 💡
4. Dive into secondary endpoints, including itch and pain relief, and how this data compares to other major clinical trials in hand eczema treatment. 📊🔬

ABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology)

Toronto, ON

Melinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada.

Dr. Gooderham has been the principal investigator for over 200 clinical trials and she practices with a focus on inflammatory diseases of the skin. She also contributes to several peer-reviewed dermatology publications as an associate editor, reviewer, and has been an author of 205 articles. She enjoys lecturing to global audiences on new therapies for skin diseases.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

🎙️ Skin Joins Podcast Wrap-Up: Sunny Stories & Cool Pools 🌞

We welcome back Dr. Michele Ramien, who graced our podcast last July from the sunny World Congress of Dermatology in Singapore. 🌏 Fast forward, she reflects on dermatology innovation from vibrant city of San Diego! 🌴

Dr. Ramien shares a delightful (and chilly) San Diego story about renting a house wit, a freezing-cold pool, and a group of eager people determined to swim🏊‍♂️❄️

We deep dive into the exciting highlights from the American Academy of Dermatology conference. Dr. Ramien, attending AAD for the first time in a while, reveals fascinating pearls and🩺✨ innovative treatments including the potential for disease remission in young patients, as well as fresh new insights on melasma and post-inflammatory hyperpigmentation in Asian skin 🌟

Dr. Ramien also touches on the importance of adapting treatments for different skin types and the promising future of pediatric dermatology. 👶💡

Learning Objectives:

1. 🌍 Understand the global advancements in dermatology from the AAD conference.
2. 🧴 Learn about innovative treatments for atopic dermatitis, including pediatric applications.
3. 🎨 Explore the management of melasma and post-inflammatory hyperpigmentation in diverse skin types.
4. 🧒 Discover the potential for disease remission in young patients with early and targeted treatments.

Tune in for a blend of personal stories, professional insights, and a sneak peek into the future of dermatological treatments. 📚🔍

Stay tuned, stay informed, and as always, keep your skin happy 🌟🧴

Supported by an IME Grant from Pfizer

ABOUT Dr. Michele L. Ramien

Pediatric Dermatologist | Calgary

Dr. Michele Ramien is an academic dermatologist based at the Alberta Children’s Hospital, in the foothills of the Rocky Mountains in Calgary, Canada. She has both pediatric and general medical dermatology practices, with a focus on teaching and mentoring the next generations and research interests in eczema management, patient education, and severe cutaneous reactions in children.

Dr. Ramien enjoys volunteer leadership positions as a way to meet colleagues across the country, like-minded and not, who believe that a small group of thoughtful, committed individuals can change and improve dermatology and delivery of care in Canada.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca